GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (NAS:DCPH) » Definitions » Price-to-Tangible-Book

Deciphera Pharmaceuticals (Deciphera Pharmaceuticals) Price-to-Tangible-Book

: 3.37 (As of Today)
View and export this data going back to 2017. Start your Free Trial

As of today (2024-04-19), Deciphera Pharmaceuticals's share price is $14.67. Deciphera Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $4.36. Hence, Deciphera Pharmaceuticals's Price to Tangible Book Ratio of today is 3.37.

The historical rank and industry rank for Deciphera Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

DCPH' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.88   Med: 3.7   Max: 6.05
Current: 3.36

During the past 9 years, Deciphera Pharmaceuticals's highest Price to Tangible Book Ratio was 6.05. The lowest was 1.88. And the median was 3.70.

DCPH's Price-to-Tangible-Book is ranked worse than
65.71% of 872 companies
in the Drug Manufacturers industry
Industry Median: 2.285 vs DCPH: 3.36

A closely related ratio is called PB Ratio. As of today, Deciphera Pharmaceuticals's share price is $14.67. Deciphera Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $4.36. Hence, Deciphera Pharmaceuticals's P/B Ratio of today is 3.37.


Deciphera Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Deciphera Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deciphera Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.88 6.05 1.88 3.24 3.70

Deciphera Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.24 2.76 2.74 2.67 3.70

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Deciphera Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Deciphera Pharmaceuticals Price-to-Tangible-Book Distribution

For the Drug Manufacturers industry and Healthcare sector, Deciphera Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Deciphera Pharmaceuticals's Price-to-Tangible-Book falls into.



Deciphera Pharmaceuticals Price-to-Tangible-Book Calculation

Deciphera Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=14.67/4.359
=3.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Deciphera Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Deciphera Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Deciphera Pharmaceuticals (Deciphera Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
200 Smith Street, Waltham, MA, USA, 02451
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.
Executives
Jama Pitman officer: SVP, Regulatory & Quality C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Daniel C. Martin officer: Chief Commercial Officer C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Thomas Patrick Kelly officer: Chief Financial Officer C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Matthew L Sherman officer: EVP & Chief Medical Officer C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Steven L. Hoerter director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Dashyant Dhanak officer: EVP & Chief Scientific Officer C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Daniel Lee Flynn officer: Chief Scientific Officer C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Franklin Stuart Friedman director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Dennis Leo Walsh director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Brightstar Associates Llc 10 percent owner 1020 CENTRAL STREET, KANSAS CITY MO 64105
James Arthur Bristol director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Michael Douglas Taylor director, officer: See Remarks C/O DECIPHERA PHARMACEUTICALS, LLC, 500 TOTTEN POND ROAD, WALTHAM MA 02451
Patricia L Allen director C/O DECIPHERA PHARMACEUTICALS, INC, 200 SMITH STREET, WALTHAM MA 02451
Christopher John Morl officer: Chief Business Officer C/O DECIPHERA PHARMACEUTICALS, LLC, 500 TOTTEN POND ROAD, WALTHAM MA 02451
Ron Squarer director C/O ADC THERAPEUTICS SA, BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES V8 1066